Prediction medicine: biomarkers, risk calculators and magnetic resonance imaging as risk stratification tools in prostate cancer diagnosis
DF Osses, MJ Roobol, IG Schoots - International journal of molecular …, 2019 - mdpi.com
This review discusses the most recent evidence for currently available risk stratification tools
in the detection of clinically significant prostate cancer (csPCa), and evaluates diagnostic …
in the detection of clinically significant prostate cancer (csPCa), and evaluates diagnostic …
Prostate cancer liquid biopsy biomarkers' clinical utility in diagnosis and prognosis
Simple Summary In prostate cancer, overdiagnosis and overtreatment is a common problem
for clinicians. Accurate diagnosis and prognosis are essential to avoid unnecessary biopsy …
for clinicians. Accurate diagnosis and prognosis are essential to avoid unnecessary biopsy …
SelectMDx and multiparametric magnetic resonance imaging of the prostate for men undergoing primary prostate biopsy: a prospective assessment in a multi …
Simple Summary Prostate-specific antigen and digital rectal examination, used to guide
prostate biopsy, often result in overdiagnosis of indolent prostate cancer (PCa) while …
prostate biopsy, often result in overdiagnosis of indolent prostate cancer (PCa) while …
[HTML][HTML] Diagnostic accuracy of liquid biomarkers for clinically significant prostate cancer detection: a systematic review and diagnostic meta-analysis of multiple …
Context Many liquid biomarkers have entered clinical practice with the praise to improve the
detection of clinically significant prostate cancer (csPCa), helping avoid unnecessary …
detection of clinically significant prostate cancer (csPCa), helping avoid unnecessary …
Changes in prostate-specific antigen testing relative to the revised US Preventive Services Task Force recommendation on prostate cancer screening
Importance In April 2017, the US Preventive Services Task Force (USPSTF) published a
draft guideline that reversed its 2012 guidance advising against prostate-specific antigen …
draft guideline that reversed its 2012 guidance advising against prostate-specific antigen …
[HTML][HTML] Aptamer-guided extracellular vesicle theranostics in oncology
PHL Tran, D Xiang, TNG Nguyen, TTD Tran, Q Chen… - Theranostics, 2020 - ncbi.nlm.nih.gov
In the past decade, the study of exosomes, nanosized vesicles (50-150 nm) released into
the extracellular space via the fusion of multivesicular bodies with the plasma membrane …
the extracellular space via the fusion of multivesicular bodies with the plasma membrane …
[HTML][HTML] Biomarkers for detection of clinically significant prostate cancer: contemporary clinical data and future directions
Use of serum prostate-specific antigen (PSA) testing for early detection of prostate cancer
appears to reduce cancer-specific mortality. Due to the limited specificity of PSA for clinically …
appears to reduce cancer-specific mortality. Due to the limited specificity of PSA for clinically …
Lifetime Health and Economic Outcomes of Biparametric Magnetic Resonance Imaging as First-Line Screening for Prostate Cancer: A Decision Model Analysis
Background: Contemporary prostate cancer (PCa) screening uses first-line prostate-specific
antigen (PSA) testing, possibly followed by multiparametric magnetic resonance imaging …
antigen (PSA) testing, possibly followed by multiparametric magnetic resonance imaging …
Prospective assessment of two-gene urinary test with multiparametric magnetic resonance imaging of the prostate for men undergoing primary prostate biopsy
Purpose To evaluate the diagnostic accuracy of SelectMDx and its association with
multiparametric magnetic resonance (mpMRI) in predicting prostate cancer (PCa) and …
multiparametric magnetic resonance (mpMRI) in predicting prostate cancer (PCa) and …
Serum and urine biomarkers for detecting clinically significant prostate cancer
MF Becerra, VS Atluri, AS Bhattu, S Punnen - Urologic Oncology: Seminars …, 2021 - Elsevier
Since the “prostate-specific antigen (PSA) era,” we have seen an increase in unnecessary
biopsies, which has ultimately lead to an overtreatment of low-risk cancers. Given the …
biopsies, which has ultimately lead to an overtreatment of low-risk cancers. Given the …